Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Neuroblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Yi-Zhuo Zhang, MD) · zhangyzh@sysucc.org.cn · 87342460
Contact: Principal Investigator (Yi-Zhuo Zhang, MD)

Study leads

Yizhuo Zhang
Study Chair
SunYat Sen University Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Neuroblastoma

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · San Francisco, United States

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma · Neuroblastoma Recurrent · Relapsed Neuroblastoma

Abroad (travel likely)RecruitingPHASE1

Boston, United States · Boston, United States

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

High-risk Neuroblastoma · Neuroblastoma · Childhood Neuroblastoma

Abroad (travel likely)RecruitingPHASE2

New York, United States

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Neuroblastoma

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Little Rock, United States